Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor.
We measured serum osteocalcin levels in prepubertal children with human immunodeficiency virus (HIV) infection receiving highly active antiretroviral therapy including a protease inhibitor and uninfected control children. Osteocalcin values were significantly elevated in the HIV-infected patients. Though osteocalcin serves as an index of bone formation, it likely functions as a negative regulator of bone formation. Further study is necessary to determine whether protease inhibitors normalize bone physiology or decrease bone formation and reduce bone mineral density in children receiving these therapies.
Tan
B M
BM
Department of Pediatrics, Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, FL, USA.
Nelson
R P
RP
James-Yarish
M
M
Emmanuel
P J
PJ
Schurman
S J
SJ
D023241:Antiretroviral Therapy, Highly Active; D001842:Bone and Bones / Q000378:metabolism*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015675:Osteocalcin / Q000097:blood*
D017320:HIV Protease Inhibitors; D015675:Osteocalcin